Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

Cancer Treatment Reviews
G G GomezC A Kruse

Abstract

The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modality experiments with CAIT has been a synergistic enhancement in antitumor activity. Clinical trials usually demonstrated improvement in patient quality of life, an extension of survival time, and occasional complete regression of tumor. In many animal models, this enhancement often meant the complete regression and apparent cure of tumor in the animal. One mechanism by which this synergistic enhancement takes place appears to be a suppression of tumor-associated suppressor T cell activity by the chemotherapeutic agents, thereby inducing enhanced cytolytic activity against tumor by the adoptively transferred, activated effector cells. In CAIT the most commonly used drug has been cyclophosphamide. In CIT a wide variety of chemotherapy agents have been used but none of the clinical trials made use of cyclophosphamide. Thus, direct comparisons are not possible. Suggestive of the intricate regulatory processes involved, m...Continue Reading

References

Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·A L Farone, D C Cox
Jan 1, 1991·Cancer Investigation·E M Greenspan, R Erlich
Jan 1, 1990·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·K Ota, N Ogawa
May 31, 1986·Medicina clínica·E Fernández-Cruz
Jan 1, 1982·Immunological Reviews·M J EhrkeE Mihich
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J E GoldM E Osband
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S D HeysC R Franks
Feb 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·D D TaylorJ L Weese
Feb 1, 1994·Annals of Internal Medicine·L J WongW E O'Brien
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J C YangS A Rosenberg
Jul 1, 1993·The International Journal of Neuroscience·V K GhantaR N Hiramoto
Jan 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·T DaemenG L Scherphof
Apr 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·J E GoldM E Osband
May 1, 1996·Cancer Immunology, Immunotherapy : CII·M J EhrkeE Mihich
Dec 1, 1995·International Journal of Immunopharmacology·S IidaM Saito
Dec 9, 1997·Cancer Immunology, Immunotherapy : CII·C A KruseK O Lillehei
Apr 16, 1998·International Journal of Urology : Official Journal of the Japanese Urological Association·Y TomitaK Takahashi

❮ Previous
Next ❯

Citations

Dec 16, 2004·The Journal of Clinical Investigation·Jehonathan H PinthusZelig Eshhar
Nov 18, 2008·The Journal of Urology·Kazunori HagaNoriyuki Kasahara
Nov 3, 2010·Virus Research·Liliana Soroceanu, Charles S Cobbs
Sep 18, 2004·Bioelectromagnetics·Mahendra K LoganiMarvin C Ziskin
Dec 22, 2007·Nature Reviews. Immunology·Laurence ZitvogelGuido Kroemer
Apr 4, 2015·Journal of Immunotherapy·Lingbing ZhangJeffrey A Norton
Apr 19, 2021·Journal of Nanobiotechnology·Rafieh BagherifarYousef Javadzadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.